Locally Advanced Gastric Cancer Clinical Trial
Prospective Randomized Controlled Multicenter Clinical Trial for Comparison of Safety Between Totally Laparoscopic Distal Gastrectomy(TLDG) and Laparoscopy-Assisted Distal Gastrectomy(LADG) With Billroth-II Reconstruction and D2 Lymphadenectomy for Locally Advanced Gastric Cancer
Status | Not yet recruiting |
Enrollment | 176 |
Est. completion date | |
Est. primary completion date | May 2017 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 75 Years |
Eligibility |
Inclusion Criteria: - The diagnosis of gastric cancer was confirmed by pathological examination - Preoperative staging as cT2-4aN0-3M0 according to AJCC-7th - No accompany with another cancer - ECOG 0-1 - ASA I-III - Agreement Exclusion Criteria: - Pregnant or suckling period - Patients with a history of preoperative chemoradiotherapy - Patients with unable to finish D2 lymphadenectomy or R0 resection - Laparoscopic surgery contraindications - Serious organ disfunction - Accompany with serious mental disease - Continuous treatment with steroid in 1 month - Disagreement |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Fujian Cancer Hospital |
Han G, Park JY, Kim YJ. Comparison of short-term postoperative outcomes in totally laparoscopic distal gastrectomy versus laparoscopy-assisted distal gastrectomy. J Gastric Cancer. 2014 Jun;14(2):105-10. doi: 10.5230/jgc.2014.14.2.105. Epub 2014 Jun 30. Erratum in: J Gastric Cancer. 2014 Dec;14(4):284. — View Citation
Ikeda O, Sakaguchi Y, Aoki Y, Harimoto N, Taomoto J, Masuda T, Ohga T, Adachi E, Toh Y, Okamura T, Baba H. Advantages of totally laparoscopic distal gastrectomy over laparoscopically assisted distal gastrectomy for gastric cancer. Surg Endosc. 2009 Oct;23(10):2374-9. doi: 10.1007/s00464-009-0360-3. Epub 2009 Mar 5. — View Citation
Kim BS, Yook JH, Choi YB, Kim KC, Kim MG, Kim TH, Kawada H, Kim BS. Comparison of early outcomes of intracorporeal and extracorporeal gastroduodenostomy after laparoscopic distal gastrectomy for gastric cancer. J Laparoendosc Adv Surg Tech A. 2011 Jun;21(5):387-91. doi: 10.1089/lap.2010.0515. Epub 2011 May 11. — View Citation
Kim MG, Kim KC, Kim BS, Kim TH, Kim HS, Yook JH, Kim BS. A totally laparoscopic distal gastrectomy can be an effective way of performing laparoscopic gastrectomy in obese patients (body mass index=30). World J Surg. 2011 Jun;35(6):1327-32. doi: 10.1007/s00268-011-1034-6. — View Citation
Lee J, Kim D, Kim W. Comparison of laparoscopy-assisted and totally laparoscopic Billroth-II distal gastrectomy for gastric cancer. J Korean Surg Soc. 2012 Mar;82(3):135-42. doi: 10.4174/jkss.2012.82.3.135. Epub 2012 Feb 27. — View Citation
Oki E, Sakaguchi Y, Ohgaki K, Saeki H, Chinen Y, Minami K, Sakamoto Y, Toh Y, Kusumoto T, Maehara Y. Feasibility of delta-shaped anastomoses in totally laparoscopic distal gastrectomy. Eur Surg Res. 2011;47(4):205-10. doi: 10.1159/000332850. Epub 2011 Oct 13. — View Citation
Song KY, Park CH, Kang HC, Kim JJ, Park SM, Jun KH, Chin HM, Hur H. Is totally laparoscopic gastrectomy less invasive than laparoscopy-assisted gastrectomy?: prospective, multicenter study. J Gastrointest Surg. 2008 Jun;12(6):1015-21. doi: 10.1007/s11605-008-0484-0. Epub 2008 Feb 7. — View Citation
Woo J, Lee JH, Shim KN, Jung HK, Lee HM, Lee HK. Does the Difference of Invasiveness between Totally Laparoscopic Distal Gastrectomy and Laparoscopy-Assisted Distal Gastrectomy Lead to a Difference in Early Surgical Outcomes? A Prospective Randomized Trial. Ann Surg Oncol. 2015;22(6):1836-43. doi: 10.1245/s10434-014-4229-x. Epub 2014 Nov 14. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | postoperative early anastomotic morbidity | 30 days | Yes | |
Secondary | Flatus time | 7 days | Yes | |
Secondary | Quality of life | estimated with EORTC QLQ-C30V3?EORTC QLQ-STO22 | 30 days | Yes |
Secondary | Postoperative hospital stay | 30 days | Yes | |
Secondary | Pain score | 10 days | Yes | |
Secondary | Postoperative inflammation response | using C-reactive protein?IL-6?WBC and so on postoperative 1,3,5,7 days | 10 days | Yes |
Secondary | Nutrition | NRS-2002 and PG-SGA in 30 days | 30 days | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05545436 -
Carrelizumab (PD-1) Combined With Chemotherapy in Neoadjuvant Treatment of Locally Advanced Gastric Cancer
|
Phase 2 | |
Not yet recruiting |
NCT05524974 -
Clinical Study of Camrelizumab, Apatinib Mesylate and Nab-paclitaxel Combined With Oxplatin and S-1 in the Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Genotypes
|
Phase 2 | |
Active, not recruiting |
NCT03192735 -
Apatinib Combined With SOX Neoadjuvant Therapy for Locally Advanced Gastric Cancer
|
Phase 2 | |
Recruiting |
NCT03961373 -
Standard Versus Super-extended Lymphadenectomy After Neo-adjuvant Chemotherapy for Gastric Cancer
|
Phase 3 | |
Completed |
NCT02192983 -
A Comparison of XELOX Regimen and EOX Regimen as Neoadjuvant Chemotherapy Regimen for Locally Advanced Gastric Cancer.
|
N/A | |
Not yet recruiting |
NCT05610332 -
Clinical Efficacy in Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Immunotypes
|
Phase 3 | |
Recruiting |
NCT02855788 -
Metronomic Chemotherapy in Advanced Gastric Cancer
|
Phase 2 | |
Not yet recruiting |
NCT06459921 -
Efficacy and Safety of Neoadjuvant Sintilimab Plus FLOT Versus Sintilimab Plus SOX Phase II Clinical Trial for Patients With Locally Advanced Gastric Cancer
|
Phase 2 | |
Recruiting |
NCT05141747 -
A Study of MRG002 in the Treatment of HER2-positive/HER2-low Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer.
|
Phase 2 | |
Active, not recruiting |
NCT06277453 -
Effect of Adjuvant Chemotherapy Cycles on Patients With Node-negative Gastric Cancer Following Neoadjuvant Chemotherapy
|
||
Recruiting |
NCT05528367 -
Tirelizumab in Combination With Chemoradiation in Patients With Unresectable Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
|
Phase 2 | |
Recruiting |
NCT04792515 -
Camrelizumab Combined With SOX and/or Apatinib for Locally Advanced Gastric Cancer
|
Phase 2 | |
Active, not recruiting |
NCT06235164 -
The Safety and Efficacy of Neoadjuvant Immunochemotherapy Followed by Laparoscopic Gastrectomy for Gastric Cancer
|
||
Recruiting |
NCT03322969 -
Receiving Modified Chemotherapy Followed With Radical Resection After Neoadjuvant Chemotherapy
|
Phase 2 | |
Recruiting |
NCT02302794 -
A Multicenter Clinical Trial on Laparoscopic Gastric Cancer Surgery Compared With Open Surgery
|
Phase 3 |